Biolase, Inc. · OTC:BIOLQ
Biolase — Biolase Technology — World Money Show Orlando 2012
23 slides from Biolase's conference presentation, Feb 14, 2012
Slide 1: BIOLASE Technology, Inc.
Exhibit 99.1 Orlando | February 9 – 12, 2012 • Gaylord Palms Hotel & Convention Center BIOLASE Technology, Inc. Federico Pignatelli Chairman, CEO & President NASDAQ: BLTI www.biolase.com
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation may contain forward-looking statements that are based on our current expectations, estimates and projections about our industry as well as management’s beliefs and assumptions. Words such as “anticipates,” “expects,” “intends,” “plans,”“believes,”“seeks,”“esti
Slide 3: BIOLASE is Revolutionizing Surgery in Medicine
BIOLASE is Revolutionizing Surgery in Medicine How? Through the science of WaterLase! Conventional Surgical Devices include the scalpel, high speed drill, electrosurge, electric bone saws, and heat generating lasers. • The Er,Cr:YSGG (2780nm) laser crystal has the highest level of absorption in wate
Slide 4: BIOLASE is the World Leader in Laser Dentistry
BIOLASE is the World Leader in Laser Dentistry… …and the Dental Community is the Largest Medical Community World!in the 2009 US Dental Laser Market: 2009 US Overall Dental Laser Market: Hard Hard Tissue & Soft Tissue BIOLASE 45% BIOLASE 80% Source: Biolase Technology Licensing Reports Source: iData
Slide 5: Current Line of BIOLASE Products
Current Line of BIOLASE Products All-tissue dental lasers: Ourall-tissuelasersincludeournewflagshiplaser,the revolutionary WaterLase iPlus, and the WaterLase MD Turbo. Diodesoft-tissuedentallasers:Oursofttissuelasers include the ezLase total diode solution, which offers power and portability, and th
Slide 6: Alternative and Advanced Hi-Tech Dentistry
Alternative and Advanced Hi-Tech Dentistry Using BIOLASE WaterLase Systems, including our new WaterLase iPlus System: The iPlus features an The red or green intuitive, touch-based aiming beam on the computer screen, WaterLase does not similar to a tablet cut the tissue or personal computer. generate
Slide 7: WaterLase High Speed Cutting
WaterLase High Speed Cutting PAGE 7
Slide 8: Becoming a Globally Diversified Platform Company
Becoming a Globally Diversified Platform Company In 2011: Single Product Company In 2012: Broaden Platform and Product Portfolio 1. Moved from exclusive distribution with 1. Diversify revenue base to expand Schein to direct sales and multi-distributoraddressable markets and reduce investor model. ri
Slide 9: Why BIOLASE WaterLase Technology in Dentistry?
Why BIOLASE WaterLase Technology in Dentistry? Traditional high-speed drills workbyFRICTION whichcreatesHEATwhichcausesPAIN. ThisPAINnecessitates injectionsofANESTHESIA whichresultsinPAINandNUMBLIPS. In addition, the lack of feeling from the numbing injections lead tocan THERMAL DAMAGE which can lea
Slide 10: Why Dentists Should Buy an iPlus System?
Why Dentists Should Buy an iPlus System? …WaterLase’s Tremendous Return on Investment! Monthly Lease Payment New Monthly Revenue Generated Approx. $1,000 $5,000 –$15,000 • WaterLase technology enables traditional dentists to perform procedures that they currently refer out to specialists or current
Slide 11: Patent Portfolio
Patent Portfolio Current Status: BIOLASE hasa tremendous IPportfoliowith284issuedandpendingpatents,70%ofwhich are related to our core WaterLase (Er,Cr:YSGG) technology and medical lasers. Issued Pending Total U.S. 84 53 137 International 76 71 147 Total 160 124 284 Filingcostsandmaintenance areclose
Slide 12: $50B to $100B WaterLase Market Opportunity
$50B to $100B WaterLase Market Opportunity The WaterLase’s global market opportunity is immense… because the dental community is the largest medical community in the world. Our current market penetration is approximately 3% in the US and slightly less than 1% internationally! 1 • 176,000 dentists in
Slide 13: Warning: Patients Urged to Ask their Dentists About the Risk of Cross Contamination
Warning:Patients Urged to Ask their Dentists About the Risk of Cross Contamination! Cross contamination is a huge 1,2,3,4 threat: • The CDC defines cross-contamination as the act of spreading bacteria and viruses from one surface to another. Blood-borne viruses have the ability to live on objects an
Slide 14: The Bacterial Challenge
The Bacterial Challenge Antibiotic resistance adversely impacts the health of millions of patients every year. Of the patients receiving antibiotics, 50% receive 1 unnecessary orredundant therapyr,esultinginoveruseof antibiotics. Resistance to antibiotics is high among bacteria that cause serious in
Slide 15: Eliminating the Risk of Cross Contamination
Eliminating the Risk of Cross Contamination BIOLASE is entering a new dental category utilizing WaterLase technology as it essentially eliminates the risk of cross contamination and contagion: Burs and Endo Files: WaterLase Tips: WaterLase MD™reduced E. faecalis 2.86 times more effectively than NaOC
Slide 16: Further Opportunities to Expand in Dentistry
Further Opportunities to Expand in Dentistry Patented laser toothbrush for home use: • BIOLASE is currently developing a laser toothbrush for consumer home-use in connection with a license agreement with The Proctor and Gamble Company (“P&G”). • Research indicates that a laser toothbrush for home-us
Slide 17: Diversification in 2012
Diversification in 2012 BIOLASE will diversify in 2012 and expand product sales beyond dentistry. 2011 (Projected) 2012 (Projected) WaterLase Systems ~60% ~50% Diode Systems ~19% ~15% Consumables & ~20% ~20% Other New ~1% ~15% • iPlus sales will continue grow rapidly as new products ramp enhancing r
Slide 18: 2012: Expanding Beyond Dentistry
2012: Expanding Beyond Dentistry With our patented WaterLase and diode technologies, we have created technological platforms that have the ability to extend far outside of dentistry. We expect to greatly expand our addressable markets in the coming years which, we believe, has the potential to subst
Slide 19: 2012: Expanding Beyond Dentistry (Continued)
2012:Expanding BeyondDentistry(Continued) Aesthetics: WehavevariousFDAapprovals forapplications indermatology, plasticsurgery, and oculoplastics and are currently investigating options for entering these markets in 2012. PainManagement: Weanticipatelaunching a newdeep-tissue handpieceandupgraded las
Slide 20: Quarterly Revenues
Quarterly Revenues (in Millions) $25.0 $20.0 Federico Pignatelli restored as Chairman & CEO in Aug 2010 $15.0 $10.0 Record quarter with Over 100% revenue $5.0 Federico Pignatelli interim growth to date in 2011 CEO during Q407 Direct sales ramp begins in Sep 2010 compared to 2010 $- 2004 2005 2006 20
Slide 21: Quarterly Non-GAAP Net Income
Quarterly Non-GAAP Net Income (in Millions) $4.0 $2.0 $- $(2.0) $(4.0) $(6.0) Federico Pignatelli restored as Chairman & CEO in Aug 2010 $(8.0) 2004 2005 2006 2007 2008 2009 2010 2011 Q1-Mar $ 0.783 $ (4.015) $ (1.462) $ (0.890) $ 0.985 $ (3.763) $ (4.797) $ 0.153 Q2-Jun $ 1.006 $ (6.222) $ (1.340)
Slide 22: Chart & Financial History
Chart & Financial History Aug 2010-Present 1994-2006 Pignatelli Pignatelli CEO & Exclusive distribution partnership with Chairman of the Board Henry Schein Aug 2006–Aug 2010Board Chairman 20 BLTI Revenues BLTI 15 Share Price 1998 FDA Clearance 10 WaterLase 5 Volume: Millions of Shares PAGE 22
Slide 23: BIOLASE Technology, Inc. Today
BIOLASE Technology, Inc. Today • Our 57,000 sq. ft. corporate HQ in Irvine houses finance & administrative, sales, marketing, customer care, training, manufacturing, and R&D. This facility can accommodate growth to $250 million. • ISO 9001 certified and FDA GMP with clean room operations. Company He